Your browser doesn't support javascript.
loading
Application of human induced pluripotent stem cells for modeling and treating neurodegenerative diseases.
Payne, Natalie L; Sylvain, Aude; O'Brien, Carmel; Herszfeld, Daniella; Sun, Guizhi; Bernard, Claude C A.
Afiliação
  • Payne NL; Australian Regenerative Medicine Institute, Monash University, Victoria 3800, Australia.
  • Sylvain A; Australian Regenerative Medicine Institute, Monash University, Victoria 3800, Australia.
  • O'Brien C; CSIRO, Materials and Science Engineering, Victoria 3800, Australia; Department of Anatomy and Developmental Biology, Monash University, Victoria 3800, Australia.
  • Herszfeld D; Australian Regenerative Medicine Institute, Monash University, Victoria 3800, Australia.
  • Sun G; Australian Regenerative Medicine Institute, Monash University, Victoria 3800, Australia.
  • Bernard CC; Australian Regenerative Medicine Institute, Monash University, Victoria 3800, Australia. Electronic address: claude.bernard@monash.edu.
N Biotechnol ; 32(1): 212-28, 2015 Jan 25.
Article em En | MEDLINE | ID: mdl-24815224
ABSTRACT
The advent of human induced pluripotent stem cells (hiPSCs), reprogrammed in vitro from both healthy and disease-state human somatic cells, has triggered an enormous global research effort to realize personalized regenerative medicine for numerous degenerative conditions. hiPSCs have been generated from cells of many tissue types and can be differentiated in vitro to most somatic lineages, not only for the establishment of disease models that can be utilized as novel drug screening platforms and to study the molecular and cellular processes leading to degeneration, but also for the in vivo cell-based repair or modulation of a patient's disease profile. hiPSCs derived from patients with the neurodegenerative diseases amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease and multiple sclerosis have been successfully differentiated in vitro into disease-relevant cell types, including motor neurons, dopaminergic neurons and oligodendrocytes. However, the generation of functional iPSC-derived neural cells that are capable of engraftment in humans and the identification of robust disease phenotypes for modeling neurodegeneration still require several key challenges to be addressed. Here, we discuss these challenges and summarize recent progress toward the application of iPSC technology for these four common neurodegenerative diseases.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Neurodegenerativas / Transplante de Células-Tronco / Células-Tronco Pluripotentes Induzidas / Modelos Biológicos Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Neurodegenerativas / Transplante de Células-Tronco / Células-Tronco Pluripotentes Induzidas / Modelos Biológicos Idioma: En Ano de publicação: 2015 Tipo de documento: Article